Our leadership team is structured to answer the most critical questions in a biotech investment: Is the clinical plan operationally sound? Is the underlying technology and data infrastructure scalable and secure? And are the financial projections for development realistic? We provide a holistic, 360-degree view of operational, technical, and financial risk.
Managing Partner | Clinical & Operational Due Diligence
Amin is the core of HYGEIA’s advisory practice, bringing nearly a decade of Director-level leadership experience from PAREXEL, where he managed global clinical trial portfolios valued up to $500M. He has been in the trenches of complex global trials and knows precisely what separates a successful clinical program from a costly failure. Amin specializes in pre-investment operational due diligence, portfolio company intervention, and providing the interim, C-suite leadership to guide assets through critical development milestones. His work is informed by post-graduate training in Cancer Genomics from Harvard Medical School and Financial Investing from the Ivey Business School.
Partner | Technology & Data Analytics
In modern biotech, the technology stack is as critical as the science. Sadiq leads our technical due diligence, assessing the scalability, security, and integrity of a target company’s data infrastructure. He evaluates everything from their clinical trial management systems (CTMS) and electronic data capture (EDC) platforms to their use of AI/ML in R&D. For portfolio companies, Sadiq designs and implements the board-ready business intelligence dashboards that provide investors with real-time, actionable insights into trial performance, ensuring transparent oversight.
Partner | Clinical Finance & Forecasting
A clinical trial’s success hinges on a realistic and rigorously managed budget. Kumail is a specialist in clinical finance, responsible for pressure-testing the financial models and budget projections of target investments. Leveraging his background in commercial banking and risk management, he builds sophisticated financial forecasts, models clinical trial cost scenarios, and analyzes vendor contracts to identify potential cost overruns before they impact your capital. His analysis ensures that a portfolio company’s budget aligns with the operational realities of their development plan.
